| 1 |
34732441 | Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. | 2021 Nov |
1 |
| 2 |
29674626 | Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis. | 2018 Apr 19 |
1 |
| 3 |
30501868 | Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. | 2018 Dec |
1 |
| 4 |
28291124 | MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway. | 2017 Apr |
1 |
| 5 |
25468432 | Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. | 2015 Jan |
1 |
| 6 |
24719189 | MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. | 2014 Jul |
1 |
| 7 |
23335369 | MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. | 2013 Mar 21 |
1 |
| 8 |
25073258 | An unusual case of mycosis fungoides with high proliferation index and C-MYC/8q24 translocation. | 2013 Nov-Dec |
1 |
| 9 |
22213394 | Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. | 2012 Sep 1 |
1 |
| 10 |
22851565 | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. | 2012 Oct 1 |
1 |
| 11 |
20498406 | Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. | 2010 Jul 10 |
1 |